



[288] Attorney Docket No. : 02-090-Z (NEU-02-090-Z)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bakthavatchalam et al.
Serial No. : 10/799,286
Filed : March 12, 2004
For : CAPSAICIN RECEPTOR LIGANDS
Examiner : T. Betton
Group : 1614

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Listing Under 37 CFR §1.98(a)(1))

FOREIGN PATENT DOCUMENTS

<u>Examiner</u> <u>Initial</u>		<u>Document</u> <u>Number</u>	<u>Date</u>	<u>Country</u>
_____	50.	WO02/08221	1/2002	PCT

OTHER INFORMATION

<u>Examiner</u> <u>Initial</u>	
_____	51. Biomol International's Product Data Sheet and Material Safety Data Sheet re BCTC in product brochure entitled "Vanilloids", Plymouth Meeting, Pennsylvania, June 2005.
_____	52. Ugo Basile's instruction manual entitled "Measurement of Hyperalgesia to Thermal Stimulation in Unrestrained Animals" Plantar Test (Hargreaves' Method), Catalog No. 7370, Comerio, Varese, Italy (cover and date pages).
_____	53. Behrendt et al., Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45.
_____	54. Bonache et al., Old molecules for new receptors: Trp(Nps) dipeptide derivatives as vanilloid TRPV1 channel blockers. ChemMedChem. 2006 Apr;1(4):429-38.

- _____ 55. Christoph et al., Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1. *Neurochem Int.* 2007 Jan;50(1):281-90.
- _____ 56. Cortright et al., Biochemical pharmacology of the vanilloid receptor TRPV1. An update. *Eur J Biochem.* 2004 May;271(10):1814-9.
- _____ 57. Cortright et al., TRP channels and pain. *Biochim Biophys Acta.* 2007 Mar 19.
- _____ 58. Cui et al., TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. *J Neurosci.* 2006 Sep 13;26(37):9385-93.
- _____ 59. Culshaw et al., Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain. *J Med Chem.* 2006 Jan 26;49(2):471-4.
- _____ 60. Cuypers et al., Jellyfish and other cnidarian envenomations cause pain by affecting TRPV1 channels. *FEBS Lett.* 2006 Oct 16;580(24):5728-32.
- _____ 61. Devlin, J., editor, High Throughput Screening: The Discovery of Bioactive Substances, New York, NY, Marcel Dekker, 1997 (title and copyright pages and table of contents).
- _____ 62. Doherty et al., Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. *J Med Chem.* 2007 Jul 26;50(15):3515-27.
- _____ 63. Drizin et al., Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists. *Bioorg Med Chem.* 2006 Jul 15;14(14):4740-9.
- _____ 64. El Kouhen et al., A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. *J Pharmacol Exp Ther.* 2005 Jul;314(1):400-9.

- _____ 65. Gavva et al., AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther. 2005 Apr;313(1):474-84.
- _____ 66. Gavva et al., Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. Mol Pharmacol. 2005 Dec;68(6):1524-33.
- _____ 67. Gunthorpe et al., Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther. 2007 Jun;321(3):1183-92.
- _____ 68. Harvey, A., editor, Advances in Drug Discovery Techniques, Chichester, England, Wiley & Sons, 1998 (title and copyright pages and table of contents).
- _____ 69. Honore et al., A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther. 2005 Jul;314(1):410-21.
- _____ 70. Jakab et al., Pharmacological characterization of the TRPV1 receptor antagonist JYL1421 (SC0030) in vitro and in vivo in the rat. Eur J Pharmacol. 2005 Jul 4;517(1-2):35-44.
- _____ 71. Jetter et al., N-isoquinolin-5-yl-N'-aralkyl-urea and -amide antagonists of human vanilloid receptor 1. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3053-6.
- _____ 72. Jonassohn et al., The preparation and bioactivities of (-)-isovelleral. Bioorg Med Chem. 1997 Jul;5(7):1363-7.
- _____ 73. Kanai et al., Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology. 2005 Dec;49(7):977-84.

- _____ 74. Kanai et al., Differential involvement of TRPV1 receptors at the central and peripheral nerves in CFA-induced mechanical and thermal hyperalgesia. *J Pharm Pharmacol*. 2007 May;59(5):733-8.
- _____ 75. Krause et al., Transient receptor potential ion channels as targets for the discovery of pain therapeutics. *Curr Opin Investig Drugs*. 2005 Jan;6(1):48-57.
- _____ 76. Lee et al., N-[4-(methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: analysis of structure-activity relationships for the "C-Region". *Bioorg Med Chem*. 2004 Jan 15;12(2):371-85.
- _____ 77. Lee et al., Analysis of structure-activity relationships with the N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea template for vanilloid receptor 1 antagonism. *Bioorg Med Chem*. 2004 Jul 1;12(13):3411-20.
- _____ 78. Liu et al., Molecular identification and functional characterization of a temperature-sensitive transient receptor potential channel (TRPM8) from canine. *Eur J Pharmacol*. 2006 Jan 13;530(1-2):23-32.
- _____ 79. McLeod et al., TRPV1 antagonists attenuate antigen-provoked cough in ovalbumin sensitized guinea pigs. *Cough*. 2006 Dec 15;2:10
- _____ 80. Miertus, S., and G. Fassina, editors, Combinatorial Chemistry and Technology: Principles, Methods, and Applications, New York, NY, Marcel Dekker, 1998 (title and copyright pages and table of contents).
- _____ 81. Ognyanov et al., Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles. *J Med Chem*. 2006 Jun 15;49(12):3719-42.
- _____ 82. Phelps et al., Cloning and functional characterization of dog transient receptor potential vanilloid receptor-1 (TRPV1). *Eur J Pharmacol*. 2005 Apr 18;513(1-2):57-66.

- _____ 83. Pomonis et al., BCTC, a novel orally effective VR1 antagonist with analgesic properties: in vivo characterization in models of acute inflammatory and neuropathic pain. Program 48.19. 2002 Abstract Viewer/Itinerary Planner. Washington, DC; Society for Neuroscience, 2002. On line.
- _____ 84. Pomonis et al., N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2003 Jul;306(1):387-93.
- _____ 85. Rami et al., Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3287-91.
- _____ 86. Roberts et al., TRPV1 Antagonists as a Potential Treatment for Hyperalgesia. Recent Patents on CNS Drug Discovery, 2006; 1:65-76.
- _____ 87. Saitoh et al., The differential contractile responses to capsaicin and anandamide in muscle strips isolated from the rat urinary bladder. Eur J Pharmacol. 2007 Jun 5.
- _____ 88. Shao et al., 4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):719-23.
- _____ 89. Smart et al., Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology. Eur J Pharmacol. 2001 Apr 6;417(1-2):51-8.
- _____ 90. Suh et al., Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4389-93.
- _____ 91. Sun et al., 4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3611-6.

- _____ 92. Swanson et al., Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. *J Med Chem.* 2005 Mar 24;48(6):1857-72.
- _____ 93. Szallasi et al., The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. *Nat Rev Drug Discov.* 2007 May;6(5):357-72.
- _____ 94. Tafesse et al., Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists. *Bioorg Med Chem Lett.* 2004 Nov 15;14(22):5513-9.
- _____ 95. Valenzano et al., N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. *J Pharmacol Exp Ther.* 2003 Jul;306(1):377-86.
- _____ 96. Varga et al., Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat. *Neurosci Lett.* 2005 Sep 9;385(2):137-42.
- _____ 97. Walpole et al., "Similarities and differences in the structure activity relationships of capsaicin and resiniferatoxin analogues," *J. Med. Chem.* 1996. 39:2939-2952.
- _____ 98. Wang et al., Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. *J Med Chem.* 2007 Jul 26;50(15):3528-39.
- _____ 99. Weil et al., Conservation of functional and pharmacological properties in the distantly related temperature sensors TRPV1 and TRPM8. *Mol Pharmacol.* 2005 Aug;68(2):518-27.
- _____ 100. Zheng et al., From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist. *Bioorg Med Chem Lett.* 2006 Oct 1;16(19):5217-21.